Late Breaking Abstract - Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma.

M. Panighetti (Buenos Aires, Argentina), I. Esteban (Buenos Aires, Argentina), F. Polack (Buenos Aires, Argentina)

Source: Virtual Congress 2021 – Emerging evidence on sub-acute and long COVID-19
Session: Emerging evidence on sub-acute and long COVID-19
Session type: Oral Presentation
Number: 4197

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Panighetti (Buenos Aires, Argentina), I. Esteban (Buenos Aires, Argentina), F. Polack (Buenos Aires, Argentina). Late Breaking Abstract - Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma.. 4197

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Source: Eur Respir J, 59 (2) 2101471; 10.1183/13993003.01471-2021
Year: 2022



Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Late Breaking Abstract - CPAP treatment in the very elderly with Ostructive Sleep Apnea. Pooled results from two multicenter randomized controlled trials
Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19
Year: 2021


Late Breaking Abstract - Telerehabilitation compared to centre-based pulmonary rehabilitation: a randomised controlled equivalence trial.
Source: Virtual Congress 2020 – ALERT: Ventilation and rehabilitation
Year: 2020



Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


Late Breaking Abstract - 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation: A multicenter, single blinded, superiority RCT
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough
Year: 2019



Late Breaking Abstract - Long-term safety of pirfenidone in a real-world setting: final results from the prospective, observational PASSPORT registry
Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Year: 2017


Late Breaking Abstract - 1-year radiological, functional and quality-of-life outcomes in patients with SARS-CoV-2 pneumonia: A prospective observational study.
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021



Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial
Source: Annual Congress 2010 - Clinical tuberculosis
Year: 2010

Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial
Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence
Year: 2017

Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Late Breaking Abstract - Effect on asthma control using a novel digital self-management system: a physician blinded randomised controlled cross-over pilot trial
Source: International Congress 2018 – Clinical and functional monitoring in airway disease
Year: 2018


Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021



Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Late Breaking Abstract - IPF symptoms’ course during a 3-month observation: FIBRONET observational study’s preliminary results.
Source: International Congress 2017 – Miscellaneous clinical problems
Year: 2017